Overview
Matrixyl 3000 is a combination cosmetic peptide formulation consisting of two palmitoylated peptides: Palmitoyl Tripeptide-1 (Pal-GHK) and Palmitoyl Tetrapeptide-7 (Pal-GQPR). The two peptides are proposed to work synergistically — one stimulating collagen production while the other modulates the inflammatory signaling associated with matrix degradation. FenaLife supplies Matrixyl 3000 (as the Pal-GHK + Pal-GQPR combination) for research use only.
Research Background
Matrixyl 3000 was developed by Sederma and is one of the most commercially studied cosmetic peptide combinations. Published research includes fibroblast culture studies documenting collagen and glycosaminoglycan synthesis stimulation, and human subject studies measuring wrinkle depth reduction. Pal-GQPR was added to the Matrixyl 1000 (Pal-GHK alone) formulation based on evidence that it reduces IL-6-mediated matrix-degrading signaling, providing a complementary anti-degradation mechanism to Pal-GHK’s synthesis-stimulating activity.
Studied Mechanisms
Pal-GHK stimulates fibroblast synthesis of collagen I, collagen III, fibronectin, and glycosaminoglycans. Pal-GQPR is a fragment of tenascin-C and IL-6 receptor signaling modulators that reduces IL-6-mediated inflammation and matrix metalloproteinase expression, protecting newly synthesized matrix from degradation. Together, the combination addresses both the synthesis and degradation sides of collagen homeostasis.
Molecular Profile
Supplied as a combination of Pal-GHK (MW ~578.8 g/mol) and Pal-GQPR (MW ~644.9 g/mol). Each component purity: ≥98% by HPLC.
Storage and Handling
Store at -20°C, protected from light. Both components are lipophilic; prepare stocks in ethanol or DMSO. Store solutions at 4°C and use within 4 weeks.
Research Use Only
For laboratory research purposes only. Not for human or veterinary use. Certificate of Analysis available per batch.